

(FILE 'HOME' ENTERED AT 10:19:34 ON 14 MAR 2006)

FILE 'CAPLUS' ENTERED AT 10:19:46 ON 14 MAR 2006  
STRUCTURE UPLOADED  
S L1

L1

FILE 'REGISTRY' ENTERED AT 10:20:18 ON 14 MAR 2006  
5 S L1 SSS FULL

L2

FILE 'CAPLUS' ENTERED AT 10:20:18 ON 14 MAR 2006  
5 S L2 SSS FULL  
1 S L3 AND PY<2002

L3

L4

=>

=> s l1 sss full

**REGISTRY INITIATED**

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:20:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 816 TO ITERATE

100.0% PROCESSED 816 ITERATIONS  
SEARCH TIME: 00.00.01

5 ANSWERS

L2 5 SEA SSS FUL L1

L3 5 L2

=> s l3 and py<2002  
21808062 PY<2002

L4 1 L3 AND PY<2002

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:341193 CAPLUS

DOCUMENT NUMBER: 130:357144

TITLE: Hydroxyphenylundecanes as HIV integrase inhibitors

INVENTOR(S): Bills, Gerald F.; Lingham, Russell B.; Silverman,  
Keith C.; Singh, Sheo B.; Teran, Ana; Zink, Deborah L.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: Brit. UK Pat. Appl., 40 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2327674	A1	19990203	GB 1998-15925	19980722 <--
US 6124327	A	20000926	US 1998-123180	19980727 <--
PRIORITY APPLN. INFO.:			US 1997-54074P	P 19970729
			GB 1998-226	A 19980106

GI



AB A pharmaceutical composition, useful for inhibiting HIV integrase and prevention or treatment of HIV infections, i.e. AIDS and ARC, comprises a dimerized hydroxyphenylundecane (I; R = OH, OC(O)Me) isolated from *Cytospora* culture MF6253 (ATCC 74413) in combination with antiviral, anti-infective, and/or immunomodulating agents. Biosynthetic preparation by fermentation of MF6253, isolation, and phys. and spectral properties of three dimerized hydroxyphenylundecanes, as well as an assay of HIV integrase inhibition by these compds. are presented.

IT 224186-03-2P 224186-05-4P


RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(comps. containing hydroxyphenylundecanes as HIV integrase inhibitors for treatment of HIV infections)

RN 224186-03-2 CAPLUS

CN Benzoic acid, 2-[8-(acetyloxy)undecyl]-4,6-dihydroxy-,  
8-(3,5-dihydroxyphenyl)-1-propyloctyl ester (9CI) (CA INDEX NAME)

Rotation (-).

Currently available stereo shown.




RN 224186-05-4 CAPLUS

CN Benzoic acid, 2,4-dihydroxy-6-(8-hydroxyundecyl)-, 8-(3,5-dihydroxyphenyl)-  
1-propyloctyl ester (9CI) (CA INDEX NAME)

Rotation (-).

Currently available stereo shown.



=>


=> s dsm 14453  
5600 DSM  
5 14453  
L1 1 DSM 14453  
(DSM(W)14453)

=> d ibib abs hitstr

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:308399 HCAPLUS  
DOCUMENT NUMBER: 140:338030  
TITLE: Hydroxyphenylundecane derivatives, a process for their  
production and their use  
INVENTOR(S): Hopmann, Cordula; Knauf, Martin; Broenstrup, Mark;  
Markus-Erb, Astrid; Toti, Luigi  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031123	A1	20040415	WO 2003-EP10372	20030918
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2498337	AA	20040415	CA 2003-2498337	20030918
AU 2003270218	A1	20040423	AU 2003-270218	20030918
EP 1556333	A1	20050727	EP 2003-750570	20030918
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014870	A	20050802	BR 2003-14870	20030918
JP 2006501285	T2	20060112	JP 2004-540640	20030918
US 2004122092	A1	20040624	US 2003-676715	20031001
PRIORITY APPLN. INFO.:			EP 2002-22095	A 20021002
			US 2003-439629P	P 20030113
			WO 2003-EP10372	W 20030918



OTHER SOURCE(S): MARPAT 140:338030  
GI



AB The present invention relates to novel hydroxyphenylundecane derivs. of the formula I (R=H or SO<sub>3</sub>H), a method for the preparation of said compds. by cultivation of the fungus *Cryphonectria parasitica*, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's diseases, stroke, psychosis and/or depressions.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>



```

chain nodes :
  7  8  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 32 33 34 35 36
 37 38 39 40
ring nodes :
  1  2  3  4  5  6 26 27 28 29 30 31
chain bonds :
  2-34 4-35 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 14-38 15-36 16-17
 17-18 18-19 19-20 20-21 21-22 22-23 23-24 24-25 25-28 26-32 29-36 30-33 36-37
 38-39 39-40
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31
exact/norm bonds :
  2-34 4-35 14-15 15-36 26-32 30-33 36-37
exact bonds :
  6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-38 16-17 17-18 18-19 19-20 20-21
 21-22 22-23 23-24 24-25 25-28 29-36 38-39 39-40
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31

```

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
 38:CLASS 39:CLASS 40:CLASS

```